Moderna, Inc.
320 Bent Street
Cambridge
Massachusetts
02141
United States
Tel: 617-714-6500
Fax: 617-583-1998
Website: http://www.modernatx.com/
Email: info@modernatx.com
About Moderna, Inc.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.
Our Mission: Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our Vision: Unlock the potential of mRNA Therapeutics™ by establishing an ecosystem of teams and partners that will work together to develop the broadest possible array of drugs, across diverse therapeutic areas and routes of administration, for serious diseases that are not treatable today.
146 articles with Moderna, Inc.
-
One can only hope that Moderna Therapeutics can live up to the hype, both scientifically and financially.
-
Moderna unleashed a torrent of updates yesterday.
-
Dr. Mendlein will be responsible for corporate strategy, product advancement and strategy, partnering and product protection.
-
Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference
1/2/2018
Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.
-
Moderna Publishes Preclinical Data in Cell Reports on mRNA Therapeutic to Treat Rare Liver Disease Methylmalonic Acidemia (MMA), A Disorder of Organic Acid Metabolism
12/20/2017
Moderna announced the publication of preclinical data supporting its first rare liver disease development program, an mRNA therapeutic for methylmalonic acidemia (MMA), a serious and often life-threatening organic acidemia.
-
Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine.
-
Two of the top companies in the field are German-based CureVac and U.S.-based Moderna Therapeutics.
-
Moderna CEO said the company was not likely to float its initial public offering until the company has solid data on its lead mRNA treatment.
-
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
-
3 More Moderna R&D Execs Quietly Step Down
10/18/2017
So this year, Moderna has lost the head of its cancer division, its top lawyer, and its chief business officer. -
Stephen Berenson Joins Moderna’s Board Of Directors
10/10/2017
-
Moderna Announces Publication In Molecular Therapy Characterizing Potent Immune Response Generated By Its mRNA Prophylactic Vaccines
9/26/2017
-
Secretive Moderna Shakes Up R&D Model, Shows Off Early-Stage Trial Data
9/15/2017
-
Moderna Announces Pipeline And Corporate Update
9/14/2017
-
Ex-Novartis AG Exec to Lead Moderna's Manufacturing and Operations Scale-Up
8/3/2017
-
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma
7/28/2017
-
Moncef M. Slaoui, Ph.D. Joins Moderna’s Board Of Directors
7/27/2017
-
Moderna Provides Update On mRNA Rare Disease R&D Strategy
7/27/2017
-
Publication In Cell Demonstrates Moderna’s Zika Mrna Vaccine Prevents In Utero Transmission Of Zika Virus In Mice, Protects Against Zika-Related Congenital Damage
7/13/2017
-
A Look At The Beef Between Arbutus Biopharma And Biotech Unicorn Moderna
5/17/2017